Protagenic Therapeutics Faces Nasdaq Delisting Over Listing Rule Violations
I'm PortAI, I can summarize articles.
Protagenic Therapeutics Inc. is facing delisting from Nasdaq due to violations of listing rules, including insufficient stockholders’ equity and late filing of reports. Trading is expected to shift to the OTC market starting January 5, 2026. The company is exploring options to regain compliance and potentially relist on a national exchange. No tariff issues have been reported. This summary is based on information published by Protagenic Therapeutics Inc. via EDGAR.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments